Psychiatry

A recent study found that young people with life-limiting conditions had higher prevalence rates of both anxiety and depression.

For healthcare executives at all levels, addressing burnout is an urgent priority, one directly impacting their overall mission of improving quality of care and patient experience as well as retaining physicians and advanced practitioners.

A recent study of more than 50,000 found that antidepressant use could reduce a third of deaths among diabetic patients with depression.

The NMDA receptor, in combination with rehabilitation, may serve as a powerful agent for reducing relapse rates.

The lead investigator of a new meta-analysis shared the critical need for further studies on psychotherapeutic versus pharmacological treatments for PTSD.

A new meta-analysis showed that while psychotherapeutic treatments are generally preferred, there’s a dearth of data with which to defend that decision.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

Contrary to earlier research, investigators found that medical cannabis laws do not reduce deaths caused by opioid overdoses.

Patients who self-referred themselves to a hospital for suicidal and/or self-harming actions did not improve more than patients who received standard treatment apart from hospitalization.

Children exposed in utero to valproate were most affected, but exposure to 3 other monotherapies were also associated with behavioral issues.

A new study shows that loss of phosphodiesterase, not just dopamine, indicates a worsening of motor symptoms in patients with Parkinson disease.

The nasal spray was shown to reduce relapse in patients who achieved remission or stability after 16 weeks of treatment plus antidepressant.

The approval is based on the findings of a 106-adult patient trial which assessed mean weekly headache episodes.

A new study found that elements such as birth order, low parental education, or low birthweight could increase suicide risk throughout a person’s lifespan.

A new meta-analysis determined DBS is equally useful for patients with Parkinson’s who have related mutations.

Recommended dosage varies, but effectiveness increases with dosage, necessitating conclusive research.

Investigators found that patients receiving cariprazine showed significant improvement in cognitive symptoms compared to patients receiving aripiprazole or placebo therapy.

Allergan announced the FDA approved a New Drug Application for Vraylar for the treatment of depressive episodes associated with bipolar depression.

Steven Adelsheim, MD, discusses what he believes is the need to further recognize that many mental health conditions begin to develop at a young age.

Investigators presented 2 pooled analyses at APA 2019 that explored the safety profile and efficacy of 42mg lumateperone in patients with schizophrenia

Investigators presented the results of a 4-week trial examining the efficacy of SEP-363856 at APA 2019 in San Francisco, CA.

Lori Raney, MD, of Health Management Associates in Colorado, sat down with us at APA 2019 to discuss how clinicians should address the mental health needs of an aging population.

Investigators presented data from a 2-year, open-label study into the efficacy and safety of lurasidone in children 10 to 17 years old at APA 2019.

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

Lori Raney, MD, psychiatrist and principal with Health Management Associates in CO, discuss what she believes is the most important discussion topic at APA 2019.